Etidronate_for_hypercalcemia_of_malignancy_and_osteoporosis._The_biphosphonates_are_becoming_well_established_as_effective_agents_for_the_treatment_of_metabolic_bone_diseases._Etidronate_disodium_is_the_only_biphosphonate_approved_by_the_U.S._Food_and_Drug_Administration._Accepted_indications_for_etidronate_therapy_are_symptomatic_Paget's_disease,_heterotopic_ossification_and_hypercalcemia_of_malignancy._An_unapproved,_but_apparently_successful_use_is_treatment_of_postmenopausal_osteoporosis._Both_oral_and_intravenous_preparations_are_available._Newer_biphosphonates,_which_may_be_more_efficacious_and_less_toxic_than_etidronate,_are_being_studied.